Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy

Muscle and Nerve

Volumn 32, Issue 6, 2005, Pages 775-781

  Hinkle, Richard T ^a   Dolan, Elizabeth ^a   Cody, David B ^a   Bauer, Mary Beth ^a   Isfort, Robert J ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Ariflo; Clenbuterol; Disuse atrophy; Muscle atrophy; Pentoxifylline; Phosphodiesterase 4; Rolipram; Skeletal muscle

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CILOMILAST; CLENBUTEROL; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; PENTOXIFYLLINE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; SILDENAFIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENERVATION; ENZYME INHIBITION; FEMALE; INHIBITION KINETICS; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE FORCE; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADRENERGIC BETA-AGONISTS; ANALYSIS OF VARIANCE; ANIMALS; CLENBUTEROL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTRIC STIMULATION; MICE; MUSCLE CONTRACTION; MUSCLE DENERVATION; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PHOSPHODIESTERASE INHIBITORS; RATS; SCIATIC NEUROPATHY;

EID: 28544448461     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.20416     Document Type: Article

References (34)

1. Aboudrar S, Desplanches D, Graber-von Bergen F, Favier R, Okyayuz-Baklouti I, Hoppeler H. Effects of torbafylline on muscle atrophy: prevention and recovery. Can J Physiol Pharmacol 1992;70:814-820.
2. Almendro V, Carbo N, Busquets S, Figueras M, Tessitore L, Lopez-Soriano FJ, et al. Sepsis induces DNA fragmentation in rat skeletal muscle. Eur Cytokine Networks 2003;14:256-259.
3. Appell HJ. Muscular atrophy following immobilization. A review. Sports Med 1990;10:42-58.
4. Baecker PA, Obernolte R, Bach C, Yee C, Shelton ER. Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phosphodiesterase (PDE IVD). Gene 1994;138:253-250.
5. Barnette MS. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog Drug Res 1999;53:195-229.
6. Bloom TJ. Cyclic nucleotide phosphodiesterase isozymes expressed in mouse skeletal muscle. Can J Physiol Pharmacol 2002;80:1132-1135.
7. Breuille D, Farge MC, Rose F, Arnal M, Attaix D, Obled C. Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. Am J Physiol 1993;265:E660-E666.
8. Combaret L, Ralliere C, Taillandier D, Tanaka K, Attaix D. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats. Mol Biol Reports 1999;26:95-101.
9. De Arcangelis V, Coletti D, Conti M, Lagarde M, Molinaro M, Adamo S, et al. IGF-1 induced differentiation of L6 myogenic cells requires the activity of cAMP-phosphodiesterase. Mol Biol Cell 2003;14:1392-1404.
10. Enoksson S, Degerman E, Hagstrom-Toft E, Large V, Arner P. Various phosphodiesterase subtypes mediate the in vivo anti-lipolytic effect of insulin on adipose tissue and skeletal muscle in man. Diabetologia 1998;41:500-508.
11. Essayan DM. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol 1999;57:965-973.
12. Flores EA, Bistrian BR, Pomposelli JJ, Dinarello CA, Blackburn GL, Istfan NW. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest 1989;83:1614-1622.
13. Giemhycz MA. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Invest Drugs 2001;10:1361-1379.
14. Goodman MN. Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol 1991;260:E727-E730.
15. Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, et al. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 1998;287:705-711.
16. Hinkle RT, Donnelly E, Cody DB, Sheldon RJ, Isfort, RJ. Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force. J Appl Physiol 2005;98:655-662.
17. Hinkle RT, Donnelly E, Cody DB, Samuelsson S, Lange JS, Bauer MB, et al. Activation of the CRF2 receptor modulates skeletal muscle mass under physiological and pathological conditions. Am J Physiol Endocrinol Metab 2003;285:E889-E898.
18. Hinkle RT, Hodge KM, Cody DB, Sheldon RJ, Kobilka BK, Isfort RJ. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve 2002;25:729-734.
19. Jurasinski CV, Kilpartrick L, Vary TC. Amrinone prevents muscle protein wasting during chronic sepsis. Am J Physiol 1995;268:E491-E500.
20. Losavio A, Muchnik S. Facilitation of spontaneous acetylcholine release induced by activation of cAMP in rat neuromuscular junctions. Life Sci 2000;66:2543-2556.
21. Meijsing B, Carbo N, Lopez-Soriano FJ, Argiles JM. Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats hearing the Yoshida AH-130 ascites hepatoma. Cancer Lett 2002;188:53-58.
22. Muller T, Engels P, Fozard JR. Subtypes of the type 4 cAMP phosphodiesterase: structure, regulation and selective inhibition. Trends Pharm Sci 1996;17:294-298.
23. Naro F, Sette C, Vicini E, De Arcangelis V, Grange M, Conti M, et al. Involvement of type 4 cAMP phosphodiesterase in the myogenic differentiation of L6 cells. Mol Biol Cell 1999;10:4355-4367.
24. Navegantes LC, Resano NM, Baviera AM, Migliorini RH, Kettelhut IC. Effect of sympathetic denervation on the rate of protein synthesis in rat skeletal muscle. Am J Physiol Endocrinol Metab 2004;286:E642-E647.
25. Navegantes LC, Resano NM, Migliorini RH, Kettelhut IC. Role of adrenoceptors and cAMP on the catecholamine-induced inhibition of proteolysis in rat skeletal muscle. Am J Physiol Endocrinol Metab 2001;280:E553-E668.
26. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987;50:555-563.
27. Shepherd M, McSorley T, Olsen AE, Johnston LA, Thomson NC, Baillie GS, et al. Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. Biochem J 2003;370:429-438.
28. Sneddon AA, Delday MI, Steven J, Maltin CA. Elevated IGF-II mRNA and phosphorylation of 4E-BP1 and p70(S6k) in muscle showing clenbuterol-induced anabolism. Am J Physiol Endocrinol Metab 2001;281:E676-E682.
29. Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new function. Curr Opin Cell Biol 2000;12:174-179.
30. Tessitore L, Costelli P, Bonetti C, Baccino FM. Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch Biochem Biophys 1993;306:52-58.
31. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999;12:131-135.
32. Torphy TJ, Page C. Phosphodiesterases: the journey towards therapeutics. Trends Pharm Sci 2000;21:157-159.
33. Vary T, Dardevet D, Grizard J, Voisin L, Buffiere C, Denis P, et al. Pentoxifylline improves insulin action limiting skeletal muscle catabolism after infection. J Endocrinol 1999;163:15-24.
34. Warren RS, Starnes HF, Gabrilove JL, Oettgen HF, Brennan MF. The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg 1987;122:1396-1400.